
The associate professor of medicine at Siteman Cancer Center and WUSTL discussed further research to be done with CAR T-cell therapies.

The associate professor of medicine at Siteman Cancer Center and WUSTL discussed further research to be done with CAR T-cell therapies.

The associate professor of medicine at Siteman Cancer Center and WUSTL discussed updated data from a study of NT-I7 and tisa-cel presented at ASH 2022.

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the safety of chimeric antigen receptor (CAR)-T cell therapy in hematologic malignancies.

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the logistics of chimeric antigen receptor (CAR) T-cell therapy.

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses ways of reducing the cost of chimeric antigen receptor (CAR) T-cell therapy.

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the potential development of chimeric antigen receptor (CAR) T cells in solid tumors.

Published: January 23rd 2019 | Updated:

Published: November 8th 2018 | Updated:

Published: February 13th 2019 | Updated:

Published: December 20th 2018 | Updated: